TA-NIC

TA-NICis a proprietaryvaccinein development similar toTA-CDbut being used to create human anti-nicotineantibodiesin a person to destroynicotinein the human body so that it is no longer effective.

TA-NIC is a vaccine in development as an aid toquitting smokingin motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into thebrainand thus reducing thepositive reinforcementandaddictionassociated with nicotine andcigarette smoking.It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use othertobacco products. Treatment with TA-NIC is expected to be part of a comprehensive smoking cessation management program that includes other supportive measures.

Results from its clinical trials are not publicly available, although one of its developers, Thomas Kosten, disclosed in an email that the vaccine was not found to be effective enough to continue development.